DigestRedComo funciona
Red
/
Empresas
Ac
No verificado

Accord Healthcare

Sobre qué escribimos

BiologíaEconomíaFarmacéuticaSanidadStart-up

8 Comunicados de prensa

Ver todos los comunicados de prensa
02/04/2025
Farmacéutica
Sanidad
Accord Healthcare Receives Positive CHMP Opinion for Denosumab, Osvyrti®, and Jubereq®
Fuente
Accord Healthcare
Editor
PR News Wire
1.00
0
06/02/2025
Farmacéutica
Sanidad
Biología
Accord Healthcare: Hetronifly® (Serplulimab) receives Marketing Authorisation from the European Commission (EC), for the treatment of Extensive-Stage Small Cell Lung Cancer (ES- SCLC)
Fuente
Accord Healthcare
Editor
PR News Wire
1.00
0
Press Release cover image
31/01/2025
Farmacéutica
Sanidad
Economía
Start-up
Accord Healthcare launches Disulfiram in the United Kingdom, indicated as a supportive agent in the treatment of alcoholism
Fuente
Accord Healthcare
Editor
PR News Wire
1.00
0
Press Release cover image
16/12/2024
Farmacéutica
Sanidad
Biología
Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®
Fuente
Accord Healthcare
Editor
PR News Wire
1.00
0
01/11/2024
Farmacéutica
Sanidad
Empresas
Administración de Empresas
Accord Healthcare unlocks £50m government fund to boost medicines manufacturing in the North-East
Fuente
Accord Healthcare
Editor
PR News Wire
1.00
0
19/10/2024
Farmacéutica
Sanidad
Biología
Accord Healthcare receives positive CHMP opinion for IMULDOSA®, a ustekinumab biosimilar to Stelara®
Fuente
Accord Healthcare
Editor
PR News Wire
1.00
0
21/09/2024
Farmacéutica
Sanidad
Economía
Start-up
Biología
Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as HANSIZHUANG in China) in European markets as First-Line Treatment for adult patients with Extensive-Stage Small Cell Lung Cancer
Fuente
Accord Healthcare
Editor
PR News Wire
1.00
0
14/08/2024
Farmacéutica
Sanidad
Economía
Start-up
NICE recommends ORGOVYX® (relugolix) as the first oral ADT treatment for hormone sensitive prostate cancer in England
Fuente
Accord Healthcare
Editor
PR News Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0